Drug Database
BU

butocin (butocin / Benin)

✓ Approved

Spofa · HPRT1 · Small Molecule

What is butocin?

butocin is a small molecule developed by Spofa. It is approved for therapeutic indications.

Drug Profile

Brand Namesbutocin, Benin
CompanySpofa
Drug ClassSmall Molecule
Molecular TargetHPRT1
StatusApproved

Mechanism of Action

Molecular Targets

butocin acts on 1 molecular target:

HPRT1hypoxanthine phosphoribosyltransferase 1 (HGPRT, HPRT)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

butocin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasm malignant✓ Approved

Related Research Articles

PubMedFolia microbiologica1995-01-01

Mutagenicity of cytostatic drugs in a bacterial system. I. Ames test.

Marhan J J

A set of nine cytostatic drugs were tested in the standard plate incorporation method of Ames reversion test using four Salmonella typhimurium his strains. Six of them were classical and commonly used cytostatics, three (cloturin, butocin and oracin) are at different stages of development. The results showed 6-mercaptopurine, cloturin, adriamycin, mitoxantron, cyclophosphamide and lomustine to be mutagenic; butocin, oracin and tris(2-chloroethyl)amine were negative in this test.

PubMedFolia microbiologica1995-01-01

Mutagenicity of cytostatic drugs in a bacterial system. II. DNA-repair test.

Marhan J J

A liquid micromethod modification of the DNA-repair test using an automatic growth analyzer was developed. The wild strain Escherichia coli WP2 and six repair-deficient isogenic test strains were used. To compare this repair test with the conventional plate Ames test, a set of nine cytostatics were tested. Cloturin, adriamycin, mitoxantron, oracin, lomustine and tris(2-chloroethyl)amine were found to be positive, and 6-mercaptopurine, butocin and cyclophosphamide negative. The experimental micromethod appears to be useful for assessing the differential lethality in bacteria and can be combined in any short-term test system to predict genotoxicity.

PubMedCeskoslovenska farmacie1985-07-01

[Determination of the tolerance and pharmacokinetics of butocin in persons with progressive polyarthritis].

Buchar E E, Perlík F F, Novotná P P, Janků I I

PubMedArzneimittel-Forschung1979-01-01

[Binding of butocin to serum proteins (author's transl)].

Grafnetterová J J, Kalousek I I, Vodrázka Z Z, Smahel O O

The binding of N-[-5-(6-purinylthio)-valeryl]-glycin ethylester (butocin, PVG) to serum proteins and pure human albumin was studied using the method of equilibrium dialysis. Its binding to protein in sera diluted 1:1 of 10 patients with malignant disease averaged 48.4 +/- 7.07%. At the butocin concentration of 20 micrograms/ml an average of 36% of butocin were bound to pure albumin. Only a small portion was bound to globulin fractions. Measurements of the saturation curve showed butocin to be bound to albumin molecule by one binding centre with a microscopic association constant kappa = 1.7 . 10(3) mol/l.

PubMedNeoplasma1978-01-01

Dominant-lethal assay of selected cytostatics.

Sýkora I I, Gandalovicová D D

Dominant-lethal assays in male mice were made with the following cytostatics: Cyclophosphamide, TS-160, Edikron, Penberol, Cytembena, Mercaptopurine, Butocin, and Damvar. The cytostatics were administered mostly for 14-day periods, with the exception of Butocin (7 days) and high doses of Cyclophosphamide and TS-160 (single administrations). From the first day of administration on, the males were mated with intact females mostly at eight one-week intervals, and the quality of pregnancy was checked. Antifertility effects were found with TS 160, Penberol (at high dosage), and Mercaptopurine. Effects on permiogenesis with genetic risk were found with Cyclophosphamide, TS-160, Mercaptopurine, and less marked ones also with Cytembena. The effects were mostly manifested by increases in the numbers of early fetal resorptions, and less frequently by preimplantation loss of ova. No genetic risk was revealed by the assay in the cytostatics Edikron, Penberol, Butocin, and Damvar.

PubMedSbornik lekarsky1976-08-01

[Clinical experience with butocin in the treatment of malignant tumours of the female genitalia (author's transl)].

Dvorák O O, Slavík V V

+6 more articles available with a free account

Sign up free to view all articles →

Ask about butocin